Investigating the 1-year decline in midbrain-to-pons ratio in the differential diagnosis of PSP and IPD.

Diagnosis, Differential Humans Magnetic Resonance Imaging Mesencephalon / diagnostic imaging Parkinson Disease / diagnostic imaging Pons Supranuclear Palsy, Progressive / diagnostic imaging
Atypical parkinsonism Idiopathic Parkinson’s disease MRI Midbrain-to-pons ratio Progressive supranuclear palsy

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 18 06 2020
accepted: 19 11 2020
revised: 10 11 2020
pubmed: 6 12 2020
medline: 22 6 2021
entrez: 5 12 2020
Statut: ppublish

Résumé

A reliable measure of PSP-specific midbrain atrophy, the midbrain-to-pons ratio (MTPR) has been reported to support the differential diagnosis of progressive supranuclear palsy (PSP) from idiopathic Parkinson's disease (IPD). Since longitudinal analyses are lacking so far, the present study aimed to evaluate the diagnostic value of the relative change of MTPR (relΔt_MTPR) over a 1-year period in patients with PSP, IPD, and healthy controls (HC). Midsagittal individual MRIs of patients with PSP (n = 15), IPD (n = 15), and healthy controls (HC; n = 15) were assessed and the MTPR at baseline and after 1 year were defined. The diagnostic accuracy of the MTPR and its relative change were evaluated using ROC curve analyses. PSP-patients had a significantly lower MTPR at baseline (M = 0.45 ± 0.06), compared to both non-PSP groups (F (2, 41) = 62.82, p < 0.001), with an overall predictive accuracy of 95.6% for an MTPR ≤ 0.54. PSP-patients also presented a significantly stronger 1-year decline in MTPR compared to IPD (p < 0.001). Though predictive accuracy of relΔ The present results indicate that the relΔ

Sections du résumé

BACKGROUND BACKGROUND
A reliable measure of PSP-specific midbrain atrophy, the midbrain-to-pons ratio (MTPR) has been reported to support the differential diagnosis of progressive supranuclear palsy (PSP) from idiopathic Parkinson's disease (IPD). Since longitudinal analyses are lacking so far, the present study aimed to evaluate the diagnostic value of the relative change of MTPR (relΔt_MTPR) over a 1-year period in patients with PSP, IPD, and healthy controls (HC).
METHODS METHODS
Midsagittal individual MRIs of patients with PSP (n = 15), IPD (n = 15), and healthy controls (HC; n = 15) were assessed and the MTPR at baseline and after 1 year were defined. The diagnostic accuracy of the MTPR and its relative change were evaluated using ROC curve analyses.
RESULTS RESULTS
PSP-patients had a significantly lower MTPR at baseline (M = 0.45 ± 0.06), compared to both non-PSP groups (F (2, 41) = 62.82, p < 0.001), with an overall predictive accuracy of 95.6% for an MTPR ≤ 0.54. PSP-patients also presented a significantly stronger 1-year decline in MTPR compared to IPD (p < 0.001). Though predictive accuracy of relΔ
CONCLUSION CONCLUSIONS
The present results indicate that the relΔ

Identifiants

DOI: 10.1007/s00415-020-10327-2 PMID: 33277666 PMC: PMC7990839
pubmed: 33277666
doi: 10.1007/s00415-020-10327-2
pii: 10.1007/s00415-020-10327-2
pmc: PMC7990839
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1526-1532

Références

Williams DR, de Silva R, Paviour DC et al (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 128(6):1247–1258
doi: 10.1093/brain/awh488
Litvan I (2003) Update on epidemiological aspects of progressive supranuclear palsy. Mov Disord 18(Suppl. 6):43–50
doi: 10.1002/mds.10562
McFarland NR (2016) Diagnostic approach to atypical parkinsonian syndromes. CONTINUUM Lifelong Learn Neurol 22(4 Movement disorders):1117
doi: 10.1212/CON.0000000000000348
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
doi: 10.1136/jnnp.55.3.181
Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376
doi: 10.1136/jnnp.2007.131045
Poewe W, Wenning G (2002) The differential diagnosis of Parkinson’s disease. Eur J Neurol 9:23–30
doi: 10.1046/j.1468-1331.9.s3.3.x
van Eimeren T, Antonini A, Berg D et al (2019a) Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a neuroimaging biomarker utility system. Alzheimer’s Dement Diagn Assess Dis Monit 11:301–309
Seppi K, Poewe W (2010) Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin 20(1):29–55
doi: 10.1016/j.nic.2009.08.016
Quattrone A, Nicoletti G, Messina D et al (2008) MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 246:214–221
doi: 10.1148/radiol.2453061703
Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, Seppi K (2010) Significance of MRI in diagnosis and differential diagnosis of Parkinson’s disease. Neurodegener Dis 7(5):300–318
doi: 10.1159/000314495
Stamelou M, Knake S, Oertel WH et al (2011) Magnetic resonance imaging in progressive supranuclear palsy. J Neurol 258(4):549–558
doi: 10.1007/s00415-010-5865-0
Schrag A, Good CD, Miszkiel K et al (2000) Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54:697–702
doi: 10.1212/WNL.54.3.697
Focke NK, Helms G, Pantel PM et al (2011) Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging. Am J Neuroradiol 32(11):2087–2092
doi: 10.3174/ajnr.A2865
Kato N, Arai K, Hattori T (2003) Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 210(1–2):57–60
doi: 10.1016/S0022-510X(03)00014-5
Mueller C, Hussl A, Krismer F et al (2018) The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism Relat Disord 54:90–94
doi: 10.1016/j.parkreldis.2018.04.005
Oba H, Yagishita A, Terada H et al (2005) New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 64:2050–2055
doi: 10.1212/01.WNL.0000165960.04422.D0
Massey LA, Micallef C, Paviour DC et al (2012) Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 27(14):1754–1762
doi: 10.1002/mds.24968
Kaasinen V, Kangassalo N, Gardberg M et al (2015) Midbrain-to-pons ratio in autopsy-confirmed progressive supranuclear palsy: replication in an independent cohort. Neurol Sci 36(7):1251–1253
doi: 10.1007/s10072-015-2184-3
Josephs KA, Whitwell JL, Boeve BF et al (2006) Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. Ann Neurol 59(1):200–203
doi: 10.1002/ana.20707
Hwang M, Yang H, Kim Y et al (2017) (2013) Differential progression of midbrain atrophy in parkinsonism: longitudinal MRI study. Neurodegener Dis 17(1):31–37
doi: 10.1159/000448174
Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1–9
doi: 10.1212/WNL.47.1.1
Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864
doi: 10.1002/mds.26987
World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194
doi: 10.1001/jama.2013.281053
Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform 12:77
doi: 10.1186/1471-2105-12-77
Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC (2006) Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov Disord Off J Mov Disord Soc 21(7):989–996
doi: 10.1002/mds.20877
Warmuth-Metz M, Naumann M, Csoti I, Solymosi L (2001) Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 58:1076–1079
doi: 10.1001/archneur.58.7.1076
Dutt S, Binney RJ, Heuer HW et al (2016) Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology 87(19):2016
doi: 10.1212/WNL.0000000000003305
Ahn JH, Kim M, Kim JS et al (2019) Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson’s syndrome. Parkinsonism Relat Disord 66:80–86
doi: 10.1016/j.parkreldis.2019.07.009
Owens E, Krecke K, Ahlskog JE et al (2016) Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy. Parkinsonism Relat Disord 28:107–111
doi: 10.1016/j.parkreldis.2016.05.006
Fiford CM, Ridgway GR, Cash DM et al (2018) Patterns of progressive atrophy vary with age in Alzheimer’s disease patients. Neurobiol Aging 63:22–32. https://doi.org/10.1016/j.neurobiolaging.2017.11.002
doi: 10.1016/j.neurobiolaging.2017.11.002 pubmed: 29220823 pmcid: 5805840
Lambert C, Chowdhury R, Fitzgerald T et al (2013) Characterizing aging in the human brainstem using quantitative multimodal MRI analysis. Front Hum Neurosci 7:462
doi: 10.3389/fnhum.2013.00462
Luft AR, Skalej M, Schulz JB et al (1999) Patterns of age-related shrinkage in cerebellum and brainstem observed in vivo using three-dimensional MRI volumetry. Cereb Cortex 9(7):712–721
doi: 10.1093/cercor/9.7.712

Auteurs

Silja Kannenberg (S)

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.

Julian Caspers (J)

Department of Diagnostic and Interventional Radiology, Medical Faculty, University Hospital Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. julian.caspers@med.uni-duesseldorf.de.

Lars Dinkelbach (L)

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.

Alexia-S Moldovan (AS)

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.
Department of Neurology, Medical Faculty, University Hospital Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany.

Stefano Ferrea (S)

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.

Martin Südmeyer (M)

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.
Department of Neurology, Ernst Von Bergmann Hospital, Charlottenstraße 72, 14467, Potsdam, Germany.

Markus Butz (M)

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.

Alfons Schnitzler (A)

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.

Christian J Hartmann (CJ)

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.
Department of Neurology, Medical Faculty, University Hospital Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Diagnostic › Diagnostic différentiel › Investigating the 1-year decline in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Investigating the 1-year decline in...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Investigating the 1-year decline in...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Mésencéphale › Investigating the 1-year decline in...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladie de Parkinson › Investigating the 1-year decline in...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Rhombencéphale › Métencéphale › Pont › Investigating the 1-year decline in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Paralysie › Ophtalmoplégie › Paralysie supranucléaire progressive › Investigating the 1-year decline in...